中国药物警戒 ›› 2019, Vol. 16 ›› Issue (1): 27-31.

• 放射性药物安全性评价专栏 • 上一篇    下一篇

放射性药物的研究现状与前景展望

李建国1, 秦秀军1, 胡波2, 高洁1, 李梅1, 刘欢1, 安全1, 靳洪涛3,*   

  1. 1中国辐射防护研究院药物安全性评价中心 药物毒理与放射损伤药物山西省重点实验室/中国辐射防护研究院放射医学与环境医学研究所,山西 太原 030006;
    2中国辐射防护研究院辐照技术中心,山西 太原 030006;
    3中国医学科学院药物研究所,北京 100050
  • 收稿日期:2018-12-23 修回日期:2019-02-18 出版日期:2019-01-20 发布日期:2019-02-18
  • 通讯作者: 靳洪涛,男,博士,研究员·硕导,新药安全评价研究。E-mail：jinhongtao@imm.ac.cn
  • 作者简介:李建国,男,博士,研究员·硕导,放射毒理与新药安全评价研究。
  • 基金资助:
    国防科工局核能开发项目：放射性药物安全性评价关键技术研究;中国辐射防护研究院院放射性药物安全评价研究;项目：山西省科技基础条件平台项目（201805D141007）

Research Status and Prospect of Radiopharmaceuticals

LI Jianguo1, QIN Xiujun1, HU Bo2, GAO Jie1, LI Mei1, LIU Huan1, AN Quan1, JIN Hongtao3,*   

  1. 1Drug Safety Evaluation Center in China Institute for Radiation Protection; Shanxi Key Laboratory of Drug Toxicology and Drug for Radiation Injury, Division of Radiology and Environmental Medicine of China Institute for Radiation Protection, Shanxi Taiyuan 030006, China;
    2Irradiation Technology Factory,Shanxi Taiyuan 030006, China;
    3Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
  • Received:2018-12-23 Revised:2019-02-18 Online:2019-01-20 Published:2019-02-18

PDF (PC)

677

摘要： 放射性药物是指用于临床诊断或治疗的放射性核素制剂或者其标记化合物,主要包括诊断用放射性药物和治疗用放射性药物两类。随着SPECT、PET/PET-CT普及,以99mTc、18F、68Ga 为代表的诊断用放射性药物研发近年来得到了迅速发展;治疗用放射性药物近年来由于其呈现出的良好经济效益和研发潜力也日益得到重视,然而我国目前对放射性药物的研发投入及相关政策法规体系与美国、欧盟相比仍存在较大差距。本文论述了当今国内外放射性药物的研究现状和我国放射性药物的发展概况,并就存在问题和发展前景进行展望。

关键词: 放射性药物, 政策法规, 发展现状, 前景展望

Abstract: Radiopharmaceuticals refers to radionuclides for clinical diagnosis or treatment, or labeled compounds, mainly including the radiological drugs for diagnosis and radiological drugs for treatment. With the popularity of SPECT/PET/PET-CT, the research and development of diagnostic radiotherapy drugs represented by 99mTc, 18F and 68Ga have developed rapidly in recent years. In recent years, more and more attention has been paid to the research and development of therapeutic radiotherapy drugs due to their good economic benefits and research and development potential. However, there is still a big gap between China and the United States and the European Union in terms of research and development investment in radioactive drugs and relevant policies and regulations. In this paper, the present situation of radiopharmaceutical research at home and abroad and the general situation of radiopharmaceutical development in China are discussed.

Key words: radioactive drugs, policies and regulations, development status, outlook

中图分类号: